2023 World Conference on Lung Cancer (Posters)-EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer.

EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer. - PDF(Slides)

Back to course

Pdf Summary

The document discusses the rates of pathologic complete response (pCR) and major pathological response (MPR) after neoadjuvant chemo-immunotherapy for stage III non-small cell lung cancer (NSCLC). It references the IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens after Neoadjuvant Therapy by William D. Travis.<br /><br />The study includes a case series of 61 patients with locally advanced stage III NSCLC who were treated with neoadjuvant chemotherapy-immunotherapy (Ch-IO) and underwent surgical treatment. The results showed that neoadjuvant Ch-IO is becoming a preferred treatment method for resectable NSCLC, as it has shown improved pCR and MPR rates as well as improved disease-free survival (DFS) and overall survival (OS) in multiple clinical trials.<br /><br />The study found that patients with squamous cell lung cancer and a PD-L1 level over 50% benefited the most from neoadjuvant Ch-IO, with a 100% MPR rate and an 80% pCR rate. This suggests that neoadjuvant Ch-IO can make previously considered unresectable lung cancer resectable, potentially allowing these patients to be candidates for surgical treatment. However, the document notes that further study is needed to confirm these findings.<br /><br />Overall, the study highlights the effectiveness of neoadjuvant Ch-IO in treating locally advanced NSCLC and provides evidence for its potential to improve surgical outcomes in resectable NSCLC patients. It also mentions that the Moscow City Oncological Hospital 62 has 64 years of experience and treats approximately 60,000 patients and performs 10,000 operations annually. The author invites further discussion by email.

Asset Subtitle

Yana Akhmadiyarova

Meta Tag

Speaker Yana Akhmadiyarova

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

pathologic complete response

major pathological response

neoadjuvant chemo-immunotherapy

stage III non-small cell lung cancer

IASLC Multidisciplinary Recommendations

disease-free survival

overall survival

squamous cell lung cancer

resectable lung cancer

surgical treatment